Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 10Unknown 2Not yet recruiting 2Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 720Neoplasms 458Prostatic Neoplasms 397Carcinoma, Non-Small-Cell Lung 387Lung Neoplasms 308Leukemia, Myeloid, Acute 300Multiple Myeloma 269Colorectal Neoplasms 242Neoplasm Metastasis 240Pancreatic Neoplasms 236Leukemia 235Melanoma 214Lymphoma 213Precursor Cell Lymphoblastic Leukemia-Lymphoma 204Brain Neoplasms 193Recurrence 178Head and Neck Neoplasms 177Lymphoma, Non-Hodgkin 173Leukemia, Lymphocytic, Chronic, B-Cell 168Myelodysplastic Syndromes 166Ovarian Neoplasms 160Carcinoma, Hepatocellular 154Glioblastoma 149Carcinoma, Renal Cell 137Rectal Neoplasms 134Colonic Neoplasms 129Lymphoma, Large B-Cell, Diffuse 125Lymphoma, Follicular 125Hodgkin Disease 115Squamous Cell Carcinoma of Head and Neck 109

Interventions

enzalutamide 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × OTHER × Patient Preference × Clear all
NCT04409288 2024-01-05

Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer

Chinese University of Hong Kong

Phase 3 Terminated
74 enrolled
Genitourinary

Prostatic Neoplasms, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡